En el presente trabajo se evaluó los factores de riesgo cardiovascular (RC) en pacientes con VIH, para determinar el riesgo cardiovascular asociado a la terapia antirretroviral, en los pacientes del Hospital III de Emergencias Grau-EsSalud (HEG III) durante el periodo Enero-Junio del 2010. La población de estudio estuvo constituida por 90 pacientes, de ambos sexos, mayores de 18 años y menores de 65 años, con más de tres meses de iniciado el tratamiento y con estudio basal de perfil lipídico y glucosa sérica. Se revisó historias clínicas y se desarrolló la entrevista con el paciente mediante una ficha de Recolección de datos en el Servicio de Farmacia, dando como resultado que el 24,44 % de la población estudiada (22 pacientes) desarrollaron un incremento en los valores de riesgo cardiovascular con respecto al riesgo cardiovascular medio a 10 años de acuerdo al estudio de Framingham y se observó un odds ratio (OR) de 15,46; lo que significa que el riesgo de hacer un RC elevado en los pacientes que tuvieron terapia antiretroviral con uso de inhibidores de proteasa (IP) es 15,46 veces más en relación a los pacientes que tuvieron terapia antiretroviral sin uso de IP. En el presente estudio, mediante prueba estadística se evidencia el uso de antirretrovirales inhibidores de proteasa (IP) como un factor de riesgo cardiovascular. / Presently work was evaluated the factors of cardiovascular risk in patient with HIV, to determine the cardiovascular risk associated to the therapy antirretroviral and to determine the incidence of the metabolic syndrome, in the patients of the Hospital III of Emergencies Grau-EsSalud during the period January-June of the 2010. The study population was constituted by 90 patients, of both sexes, bigger than 18 years and smaller than 65 years, with more than three months of initiate the treatment and with basal study of lipid profile and glucose serum. It was revised clinical histories and the interview was developed with the patient by means of a record of Gathering of data in the Service of Pharmacy, giving as a result that the studied population's 24, 44 % (22 patients) they developed an increment in the values of cardiovascular risk with regard to the half cardiovascular risk to 10 years according to the study of Framingham and found an odds ratio (OR) of 15.46, which means that the risk of making a RC high in patients who were using antiretroviral therapy with protease inhibitors (PI) is 15.46 times more in relation to patients who were antiretroviral therapy without PI. In the present study, through statistical test demonstrates the use of antiretroviral protease inhibitors (PI) as a cardiovascular risk factor. / Tesis
| Identifer | oai:union.ndltd.org:Cybertesis/oai:cybertesis.unmsm.edu.pe:cybertesis/3412 |
| Date | January 2013 |
| Creators | Amarillo Gutierrez, Janet Maritza, Tucunango Quispe, José Luis |
| Contributors | Rojas Ríos, Luis Alberto |
| Publisher | Universidad Nacional Mayor de San Marcos |
| Source Sets | Universidad Nacional Mayor de San Marcos - SISBIB PERU |
| Language | Spanish |
| Detected Language | English |
| Type | info:eu-repo/semantics/bachelorThesis |
| Format | application/pdf |
| Source | Repositorio de Tesis - UNMSM, Universidad Nacional Mayor de San Marcos |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0027 seconds